Maitreya Medicare (MAITREYA) Q2 FY27's Loss Narrows on Higher Revenue, But Debt Costs Linger
The hospital chain's quarterly loss narrowed from the previous quarter as revenue rose, but high finance costs kept the bottom line in the red.
Maitreya Medicare's Q2 FY27 saw a 12% sequential revenue rise, helping narrow its net loss. Yet, significant interest expenses and a negative margin show the financial turnaround remains a work in progress.
For Maitreya Medicare, a regional hospital chain expanding its bed count, the latest quarter offered a partial recovery. Revenue climbed from a weak base, but the company's heavy debt load and the costs of funding its expansion kept the bottom line firmly in the red.
The numbers tell a story of two steps forward and one step back. Revenue for the September quarter rose 12% sequentially to ₹23.68 crore, though it was essentially flat compared to the same period last year. The net loss, however, narrowed significantly to ₹0.94 crore from a ₹2.43 crore loss in the prior March quarter. This improvement looks less encouraging year-on-year, as the net loss widened from a marginal ₹0.04 crore loss in Q2 FY26.
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin %
| Metric | CurrentQ2 FY27 | Same quarter LYQ2 FY26 |
|---|---|---|
| Revenue (₹ Cr) | 23.68YoY -0.1% | 23.70 |
| Profit (₹ Cr) | -0.94YoY -2250% | -0.04 |
| Net Profit Margin % | -4.0YoY -1900% | -0.2 |
Why the loss persists despite higher sales
The sequential revenue gain, reported by FlashFinance, stemmed from a recovery in operations and the contribution from new facilities. The company has been actively expanding, most notably with a new 125-bed owned hospital in Valsad that opened in March 2026. It also runs several hospitals under asset-light operation-and-management agreements in cities like Mumbai and Varanasi.
Yet, this top-line progress is being heavily offset by finance costs. Borrowings stood at ₹23.1 crore as of March 2026, according to FlashFinance. The interest expense from this debt, alongside other costs, continues to drag profitability below the operating line. This explains why the net profit margin fell 380 basis points year-on-year to -4.0%, even as the operating margin reportedly improved.
The expansion balancing act
Maitreya Medicare's strategy hinges on this expansion, funded partly by the complete deployment of its ₹14.89 crore IPO proceeds. The capital is going into new owned facilities like the Valsad hospital and into funding the working capital needs of its growing network. The model is a mix of capital-intensive owned beds and lighter partnership models.
Live Chart
· MAITREYA
(BSE)
ISIN: INE0PLQ01011
The catch is that this growth is currently debt-funded and comes with a high cost of capital. Until the new beds reach sufficient occupancy and the partnership revenues scale up meaningfully, the interest burden will likely continue to pressure earnings. The trailing twelve-month figures show the scale of the challenge: a net loss of ₹3.20 crore on revenue of ₹90.83 crore.
Key Points
- Revenue recovered 12% quarter-on-quarter to ₹23.68 crore, though year-on-year growth was stagnant.
- The net loss narrowed to ₹0.94 crore from a deeper loss in Q4 FY26, but widened compared to Q2 FY26.
- High finance costs, linked to borrowings of ₹23.1 crore, are a major drag on profitability despite operational improvement.
- The company is in an expansion phase, having fully deployed IPO funds into new hospitals and working capital.
Hexa Perspective
This quarter underscores the transition Maitreya Medicare is navigating. Operational momentum is building, as seen in the sequential revenue pickup. However, the financial structure is working against it, with debt costs consuming the benefits of that growth.
The path to sustained profitability now depends on two factors: the new Valsad hospital ramping up occupancy quickly to boost owned revenue, and the asset-light partnerships in Mumbai and Varanasi generating higher-margin service fees. Until these new streams mature, the interest coverage ratio—which was negative for FY26—will remain a key watchpoint for investors weighing the company's growth story against its balance sheet strain.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.